Lal is the CEO and Co-Founder of GEn1E Lifesciences, a clinical-stage biotech company dedicated to developing innovative immunomodulatory therapies for rare and inflammatory diseases. With over 20 years of experience in the biotech and pharmaceutical industries, she is passionate about bringing affordable, effective healthcare solutions to patients.

Lal has a proven track record in drug development, having led teams from preclinical research to regulatory approval. Lal has filed over 15 Investigational New Drug Applications (INDs) in various therapeutic areas, including neurology, inflammation, virology, pain, and oncology. Two of the compounds she has worked on—Kaletra for HIV and Horizant (Regnite in Japan) for Restless Legs Syndrome and Post-Herpetic Neuralgia—have received regulatory approval from the US FDA and the Japanese Ministry of Health and Welfare.

Lal holds a doctorate in Pharmaceutical Sciences and Pharmacology from the University of Maryland, a Master’s in Pharmacology from the University of Arizona, and a Master’s in Management from Stanford University’s MSx Program.